IL113901D0 - 1-phenyl-3-dimethylaminopropane compounds their preparation and use - Google Patents

1-phenyl-3-dimethylaminopropane compounds their preparation and use

Info

Publication number
IL113901D0
IL113901D0 IL11390195A IL11390195A IL113901D0 IL 113901 D0 IL113901 D0 IL 113901D0 IL 11390195 A IL11390195 A IL 11390195A IL 11390195 A IL11390195 A IL 11390195A IL 113901 D0 IL113901 D0 IL 113901D0
Authority
IL
Israel
Prior art keywords
phenyl
preparation
use
dimethylaminopropane compounds
dimethylaminopropane
Prior art date
Application number
IL11390195A
Other versions
IL113901A (en
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE4426245A priority Critical patent/DE4426245A1/en
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of IL113901D0 publication Critical patent/IL113901D0/en
Publication of IL113901A publication Critical patent/IL113901A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/62Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/10Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/33Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
    • C07C323/35Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group
    • C07C323/36Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group the sulfur atom of the sulfide group being further bound to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
IL11390195A 1994-07-23 1995-05-29 1-Phenyl-3- dimethylaminopropane derivatives their preparation and pharmacemtical compositions containing them IL113901A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE4426245A DE4426245A1 (en) 1994-07-23 1994-07-23 1-phenyl-3-dimethylaminopropane compounds having pharmacological activity

Publications (2)

Publication Number Publication Date
IL113901D0 true IL113901D0 (en) 1995-08-31
IL113901A IL113901A (en) 1999-05-09

Family

ID=6524045

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11390195A IL113901A (en) 1994-07-23 1995-05-29 1-Phenyl-3- dimethylaminopropane derivatives their preparation and pharmacemtical compositions containing them

Country Status (28)

Country Link
US (3) US6248737B1 (en)
EP (1) EP0693475B1 (en)
JP (2) JP4034366B2 (en)
KR (1) KR100364465B1 (en)
CN (1) CN1077566C (en)
AT (1) AT163176T (en)
AU (1) AU685644B2 (en)
BR (1) BR9502390A (en)
CA (1) CA2154424C (en)
CO (1) CO4410179A1 (en)
CZ (1) CZ286441B6 (en)
DE (2) DE4426245A1 (en)
DK (1) DK0693475T3 (en)
ES (1) ES2115298T3 (en)
FI (1) FI114704B (en)
GR (1) GR3026326T3 (en)
HK (1) HK1005062A1 (en)
HU (1) HU218481B (en)
IL (1) IL113901A (en)
LT (1) LTPA2011007I1 (en)
LU (1) LU91793I2 (en)
MY (1) MY114889A (en)
NZ (1) NZ272623A (en)
PE (1) PE34896A1 (en)
PL (1) PL181169B1 (en)
RU (1) RU2150465C1 (en)
SI (1) SI0693475T1 (en)
ZA (1) ZA9506118B (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021612A2 (en) * 1993-02-08 1995-08-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
EP0888324A1 (en) * 1996-03-08 1999-01-07 Synthelabo 2-aminoethyl-benzofuran derivatives, preparation thereof and therapeutical use thereof
FR2745815B1 (en) * 1996-03-08 1998-06-26 Synthelabo Derivatives benzofuran, their preparations and pharmaceutical compositions comprising them
DE19609847A1 (en) * 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl- (3-aryl-but-3-enyl) -amine compounds as pharmaceutical active ingredients
DE19732928C2 (en) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Use of substituted imidazolidin-2,4-dione compounds as analgesics
DE19933421A1 (en) 1999-07-16 2001-01-25 Gruenenthal Gmbh 2-benzyl-3-dimethylamino-1-phenyl-propanderi- vate
PE20010623A1 (en) * 1999-10-05 2001-07-07 Gruenenthal Chemie Use of (+) - tramadol and / or o-demetiltramadol treatment increased urinary urgency and / or urinary incontinence
DE10059412A1 (en) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of urinary incontinence
US20080057011A1 (en) * 2001-12-12 2008-03-06 L'oreal S.A., Composition structured with a polymer containing a heteroatom and an Organogelator
DE10109763A1 (en) * 2001-02-28 2002-09-05 Gruenenthal Gmbh pharmaceutical salts
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10146275A1 (en) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Combining selected opioids with muscarinic antagonists for the treatment of urinary incontinence
PE20030527A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie Pharmaceutical formulation with delayed release that contains 3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol or a pharmaceutically acceptable salt of the same and tablets for oral administration which contain
DE10161809A1 (en) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Pharmaceutical compositions, useful e.g. for the treatment of neurodegenerative diseases, psychiatric or neuropathological diseases or especially pain and epilepsy, comprise N,N'-disubstituted piperazine derivatives
DE10161644A1 (en) * 2001-12-14 2003-06-26 Gruenenthal Gmbh New N,N'-disubstituted piperazine derivatives are noradrenaline reuptake inhibitors, useful e.g. for the treatment of arrhythmia, emesis, diarrhea, inflammation or especially depression or pain
DE10163421A1 (en) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Use of (+) - (1S, 2S) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol as an antiemetic
US20050137194A1 (en) * 2002-05-29 2005-06-23 Gruenenthal Gmbh Combination of selected opioids with other active compounds for treatment of urinary incontinence
DE10224108A1 (en) * 2002-05-29 2004-01-29 Grünenthal GmbH 1-Dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol containing sustained-release drug
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US20050137145A1 (en) * 2002-05-30 2005-06-23 Gruenenthal Gmbh Metabolites of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and their use in the treatment of urinary incontinence
DE10224624A1 (en) * 2002-05-30 2003-12-11 Gruenenthal Gmbh Metabolites and prodrugs of 1-dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol
DE10224556A1 (en) * 2002-05-31 2004-01-08 Grünenthal GmbH 1-dimethylamino-3- (3-methoxy-phenyl) 2-methyl-pentan-3-ol entaltendes drug in different formulations
US7550624B2 (en) * 2002-06-06 2009-06-23 Gruenenthal Gmbh Pharmaceutically active salts and esters of 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and 3- (3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol and methods of using same
DE10225315A1 (en) * 2002-06-06 2003-12-24 Gruenenthal Gmbh Active substance salts and esters of 1-dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol and 3- (3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl) - phenol
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10228192A1 (en) * 2002-06-24 2004-01-15 Grünenthal GmbH Dosage form for oral administration of active ingredients, vitamins and / or nutrients
BR0314459A (en) * 2002-09-24 2005-07-26 Univ Virginia Commonwealth Method for lowering and controlling intraocular pressure and / or for the treatment of mammals suffering from glaucoma and compost.
AU2003283410A1 (en) 2002-11-22 2004-06-18 Grunenthal Gmbh Combination of selected analgesics and cox-ii inhibitors
DE10326097A1 (en) * 2003-06-06 2005-01-05 Grünenthal GmbH Process for the preparation of dimethyl (3-aryl-butyl) -amine compounds
DE10328316A1 (en) 2003-06-23 2005-01-20 Grünenthal GmbH Process for the preparation of dimethyl (3-aryl-butyl) -amine compounds as pharmaceutical active ingredients
DE10336400A1 (en) * 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (en) * 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102004019916A1 (en) * 2004-04-21 2005-11-17 Grünenthal GmbH Anti-abuse drug-containing patch
DE102004020220A1 (en) * 2004-04-22 2005-11-10 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
JP5420170B2 (en) * 2004-05-14 2014-02-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap Carboxamide opioid compounds
SI1612203T1 (en) * 2004-06-28 2007-12-31 Gruenenthal Chemie Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
DE102004032049A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102004032051A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
JP2008527035A (en) * 2005-01-18 2008-07-24 ユニヴァーシテイ オブ フロリダ Compositions and methods for inhibiting pain
US20060160905A1 (en) * 2005-01-18 2006-07-20 Bergeron Raymond J Jr Compositions and methods for inhibiting pain
DE102005005449A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102005033732B4 (en) * 2005-05-27 2014-02-13 Grünenthal GmbH Separation of stereoisomeric N, N-dialkylamino-2-alkyl-3-hydroxy-3-phenyl-alkanes
DE202005014347U1 (en) * 2005-09-09 2007-01-18 Grünenthal GmbH Application system for an active-ingredient release system, comprises a film-forming transparent plastic foil strip detachably connected to plaster containing an active ingredient and to controlled-release agent for the active ingredient
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
DE102005052588A1 (en) * 2005-11-02 2007-05-10 Grünenthal GmbH Process for the preparation of substituted dimethyl- (3-aryl-butyl) -amine compounds by means of homogeneous catalysis
US20070254960A1 (en) * 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
BRPI0711482B1 (en) * 2006-04-28 2019-09-17 Grünenthal GmbH Pharmaceutical combination understanding 3- (3-dimethylamine-1 ethyl-2-methyl-propil) phenol and a nsaid
DE602007011913D1 (en) * 2006-04-28 2011-02-24 Gruenenthal Gmbh Pharmaceutical combination with 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
US8138376B2 (en) * 2006-07-24 2012-03-20 Janssen Pharmaceutica, Nv Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine
TWI496762B (en) * 2006-07-24 2015-08-21 Process for the preparation of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
TWI401237B (en) * 2006-07-24 2013-07-11 Preparation of 3-[(1r, 2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol monohydrochloride
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
DE102007012165A1 (en) 2007-03-12 2008-09-18 Grünenthal GmbH Use of 1-phenyl-3-dimethylamino-propane compounds for the therapy of neuropathy pain
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
DE102007019417A1 (en) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol for the treatment of pain in osteoarthritis
US20090076164A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched tapentadol
WO2009067703A2 (en) 2007-11-23 2009-05-28 Nectid, Inc. Tapentadol compositions
CN104447360B (en) * 2007-12-07 2017-04-12 格吕伦塔尔有限公司 Crystalline modifications of (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl -propyl)-phenol
TWI454288B (en) 2008-01-25 2014-10-01 Gruenenthal Chemie Pharmaceutical dosage form
ES2599031T3 (en) 2008-05-09 2017-01-31 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spray freezing step
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010025931A2 (en) 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination
EP2352494B1 (en) 2008-10-30 2019-10-09 Grünenthal GmbH Novel and potent tapentadol dosage forms
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
CN102438607A (en) * 2009-04-30 2012-05-02 格吕伦塔尔有限公司 Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
WO2011009603A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive oploids
CN102002065B (en) * 2009-09-02 2014-09-10 上海特化医药科技有限公司 Method for preparing tapentadolhydrochloride and intermediate thereof
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
IT1397189B1 (en) 2009-12-01 2013-01-04 Archimica Srl New process for the preparation of tapentadol and its intermediates.
WO2011080756A1 (en) * 2009-12-29 2011-07-07 Ind-Swift Laboratories Limited Process for the preparation of 1-phenyl-3-dimethylaminopropane derivatives
MX2012007759A (en) * 2009-12-29 2012-08-01 Mapi Pharma Ltd Intermediate compounds and processes for the preparation of tapentadol and related compounds.
WO2011092719A2 (en) * 2010-02-01 2011-08-04 Ind-Swift Laboratories Limited Process for the preparation of l-phenyl-3-dimethylaminopropane derivatives
EP2531176B1 (en) 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
CA2790519A1 (en) 2010-03-05 2011-09-09 Actavis Group Ptc Ehf Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
AU2011241897A1 (en) 2010-04-05 2012-09-27 Actavis Group Ptc Ehf Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
US9884022B2 (en) 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2566461A2 (en) 2010-05-05 2013-03-13 Ratiopharm GmbH Solid tapentadol in non-crystalline form
ITMI20100924A1 (en) * 2010-05-21 2011-11-22 Fidia Farmaceutici New method of synthesis of the two enantiomeric forms of tapentadol
AR081931A1 (en) * 2010-06-15 2012-10-31 Gruenenthal Gmbh pharmaceutical combination
EP2792668B1 (en) 2010-06-15 2017-05-31 Grünenthal GmbH Process for the preparation of substituted 3-(1-amino-2-methyl-pentane-3-yl)phenyl compounds
ES2591354T3 (en) 2010-06-30 2016-11-28 Grünenthal GmbH Tapentadol for use in the treatment of irritable bowel syndrome
IT1401109B1 (en) 2010-07-02 2013-07-12 Archimica Srl New process for the preparation of tapentadol and its intermediates.
CA2829046A1 (en) * 2010-07-23 2012-01-26 Grunenthal Gmbh Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
EP2606030B1 (en) 2010-08-16 2016-05-18 Indoco Remedies Limited Process for the preparation of tapentadol
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CN101948397A (en) * 2010-09-07 2011-01-19 天津泰普药品科技发展有限公司 Method for preparing important intermediate of tapentadol hydrochloride analgesic
WO2012038974A1 (en) 2010-09-20 2012-03-29 Ind-Swift Laboratories Limited Process for preparing l-phenyl-3-dimethylaminopropane derivative
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
CZ303115B6 (en) * 2010-12-30 2012-04-11 Zentiva, K.S. Process for preparing (2R,3R)-N,N-dimethyl-3-(3-hydroxyphenyl)-2-methylpentylamine
CZ302992B6 (en) * 2010-12-30 2012-02-08 Zentiva, K.S. Process for preparing (2R,3R)-N,N-dimethyl-3-(hydroxyphenyl)-2-methylpentylamine (tapentadol)
WO2012101649A1 (en) 2011-01-27 2012-08-02 Symed Labs Limited A novel stereospecific synthesis of (-) (2s,3s)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl pentan-3-ol
CN102617501A (en) * 2011-01-31 2012-08-01 上海特化医药科技有限公司 Substituted valeramide compound, preparation method and application thereof
SI2680834T1 (en) 2011-03-04 2018-01-31 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
CN107088226A (en) 2011-03-04 2017-08-25 格吕伦塔尔有限公司 The parenteral of tapentadol hydrochloride
WO2012136349A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for preventing chronification of pain
WO2012136351A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for treating pain associated with trigeminal neuralgia
CN102206164A (en) * 2011-04-11 2011-10-05 中国药科大学 Method for preparing tapentadol intermediate
WO2012146978A2 (en) 2011-04-28 2012-11-01 Actavis Group Ptc Ehf A novel process for the preparation of tapentadol or a pharmaceutically acceptable salt thereof
ES2646363T3 (en) 2011-04-29 2017-12-13 Grünenthal GmbH Tapentadol for the prevention and treatment of depression and anxiety
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
US20140170209A1 (en) 2011-07-20 2014-06-19 Torrent Pharmaceuticals Ltd. Pharmaceutical invention of tapentadol
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
AU2012289763B2 (en) * 2011-07-29 2017-07-13 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
WO2013016840A1 (en) 2011-07-29 2013-02-07 安徽省新星药物开发有限责任公司 Novel intermediate used for preparing tapentadol or analogues thereof
WO2013105109A1 (en) 2011-11-09 2013-07-18 Indoco Remedies Limited Process for the preparation of tapentadol
WO2013090161A1 (en) 2011-12-12 2013-06-20 Boehringer Ingelheim International Gmbh Stereoselective synthesis of tapentadol and its salts
CN102557851B (en) * 2011-12-13 2014-03-26 安徽省新星药物开发有限责任公司 New method for synthesizing tapentadol hydrochloride and analogue of tapentadol hydrochloride
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
JP6117249B2 (en) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper resistant dosage forms comprising a pharmacologically active compound and an anionic polymer
RS57913B1 (en) 2012-04-18 2019-01-31 Gruenenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2674414A1 (en) 2012-06-15 2013-12-18 Siegfried AG Method for the preparation of 1-aryl-1-alkyl-3-dialkylaminopropane compounds
CN103159633B (en) * 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 Preparation of tapentadol and for the preparation of a compound of tapentadol
EP2872126B1 (en) 2012-07-16 2017-12-06 Grünenthal GmbH Pharmaceutical patch for transdermal administration of tapentadol
CZ304576B6 (en) * 2012-07-24 2014-07-16 Zentiva, K.S. TAPENTADOL oxalate and process for preparing thereof
BR112015009839A2 (en) 2012-11-01 2017-07-11 Torrent Pharmaceuticals Ltd tapentadol pharmaceutical composition for parenteral administration
US9090539B2 (en) 2013-05-24 2015-07-28 Ampac Fine Chemicals Llc Compounds and methods for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds
MX2015016112A (en) 2013-05-29 2016-03-31 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles.
BR112015029616A2 (en) 2013-05-29 2017-07-25 Gruenenthal Gmbh tamper-resistant dosage form with bimodal release profile
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
IN2013MU03478A (en) * 2013-11-01 2015-07-17 Sun Pharma Advanced Research Company Limited Novel intermediate of tapentadol
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
IN2013MU03670A (en) 2013-11-21 2015-07-31 Unimark Remedies Ltd. A novel process for the preparation of 1-phenyl-3-aminopropane derivatives
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3083551B1 (en) 2013-12-16 2018-02-14 Farma GRS, d.o.o. Crystalline form of tapentadol intermediate
CN104803861B (en) * 2014-01-27 2017-05-24 上海博邦医药科技有限公司 Method for synthesizing tapentadol hydrochloride
CZ307492B6 (en) 2014-02-04 2018-10-17 Zentiva, K.S. A solid form of tapentadol maleate and a method of its preparation
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
EP2942054A1 (en) 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
MX2016014738A (en) 2014-05-12 2017-03-06 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol.
CA2949422A1 (en) 2014-05-26 2015-12-03 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
EP3166923A4 (en) 2014-07-10 2018-02-21 Mallinckrodt LLC Process for preparing substituted phenylalkanes
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US20160343231A1 (en) * 2015-05-22 2016-11-24 Digi-Star, Llc Recording Mixer Rotation Rate Along with Weight of Feed and Date and Time
US10471025B2 (en) 2015-05-26 2019-11-12 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
CA2991421C (en) 2015-07-10 2019-04-30 Mallinckrodt Llc A two-step process for preparing 3-substituted phenylalkylamines
EP3445742B1 (en) 2016-04-19 2019-11-13 ratiopharm GmbH Crystalline tapentadol phosphate
US10292948B2 (en) 2017-01-11 2019-05-21 Torrent Pharmaceuticals Limited Tapentadol nasal composition
EP3568126A1 (en) 2017-01-11 2019-11-20 Torrent Pharmaceuticals Limited Tapentadol nasal composition
WO2019195775A1 (en) * 2018-04-06 2019-10-10 Flex Pharma, Inc. Tolperisone analogs and methods of use

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE124521C (en)
US2662886A (en) 1949-01-28 1953-12-15 Winthrop Stearns Inc Substituted phenylpropylamines
DE1051281B (en) * 1955-07-05 1959-02-26 Bayer Ag A process for the preparation of derivatives of 1-aryl-3-aminopropan-1-ols
US3328249A (en) 1965-06-21 1967-06-27 Sterling Drug Inc Process for counteracting depressive states
NL7403348A (en) * 1973-03-19 1974-09-23
DD124521A1 (en) 1976-03-16 1977-03-02
US4608391A (en) 1977-07-05 1986-08-26 Cornell Research Foundation Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
DE2732750A1 (en) * 1977-07-20 1979-02-08 Merck Patent Gmbh Basic thioethers and process for their manufacture
US4336269A (en) 1979-12-10 1982-06-22 Eli Lilly And Company Para-nitrophenylalkylamines
US4404222A (en) 1980-08-25 1983-09-13 American Cyanamid Company Phenylethanolamine derivatives and acid addition salts thereof for enhancing the growth rate of meat-producing animals and improving the efficiency of feed utilization thereby
DE3242922A1 (en) 1982-11-20 1984-05-24 Basf Ag Phenylpropanolamine, their production and use
IT1213219B (en) 1984-09-28 1989-12-14 Consiglio Nazionale Ricerche Derivatives amminoalchilnaftalenici to attivita 'drug.
US4843160A (en) 1984-10-01 1989-06-27 The Dow Chemical Company Preparation of alpha-aminoalkylphenols
US5059422A (en) 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5169633A (en) 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
AU623676B2 (en) 1988-08-24 1992-05-21 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
SE8800207D0 (en) * 1988-01-22 1988-01-22 Kabivitrum Ab New amines, their priority over and tell up front
US5135955A (en) 1988-04-25 1992-08-04 Eli Lilly And Company Propanamine derivatives
DK258389D0 (en) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, their preparation and use
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
ZA9106555B (en) 1990-08-27 1993-04-28 Lilly Co Eli Method of treating inflammatory bowel disease
US5281623A (en) 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
US5419993A (en) 1991-11-01 1995-05-30 Canon Kabushiki Kaisha Polyamide, electrophotographic photosensitive member employing the polyamide, and electrophotographic apparatus, device unit and facsimile machine employing the member
US5280046A (en) 1991-02-22 1994-01-18 The University Of Colorado Foundation, Inc. Method of treating type I diabetes
DE69533948T2 (en) 1994-10-21 2005-12-15 NPS Pharmaceuticals, Inc., Salt Lake City Calcium receptor active compounds
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1995021612A2 (en) * 1993-02-08 1995-08-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5322859A (en) 1993-02-08 1994-06-21 University Of Iowa Research Foundation Antiglaucoma drug composition and method
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5387614A (en) 1993-07-27 1995-02-07 University Of Iowa Research Foundation Use of sigma receptor ligands as salivary gland stimulants
DE69520430T2 (en) 1994-06-03 2001-10-18 Jmde Trust Newton Meta substituted arylalkylamines and therapeutic and diagnostic use thereof
DE19525137C2 (en) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as intermediates for the preparation of pharmaceutical agents
US5648541A (en) 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
US5830509A (en) 1996-02-07 1998-11-03 West; Daniel David Microparticle complexes with 2-amino-1-phenylpropanol materials
DE19609847A1 (en) * 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl- (3-aryl-but-3-enyl) -amine compounds as pharmaceutical active ingredients
NZ332068A (en) * 1996-04-09 2001-03-30 Smithkline Beecham Alpha, alpha-disubstituted arylalkylamine derivatives as calcilytic compounds
DE69722934D1 (en) * 1996-05-01 2003-07-24 Nps Pharma Inc Compounds that act on inorganic ion receptors
US6052610A (en) * 1998-01-09 2000-04-18 International Business Machines Corporation Magnetic catheter tracker and method therefor
US6011066A (en) 1998-02-02 2000-01-04 Veterans General Hospital-Taipei Method for treating septic shock
DE19915601A1 (en) 1999-04-07 2000-10-19 Gruenenthal Gmbh 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
TWI291871B (en) 2000-11-01 2008-01-01 Cognition Pharmaceuticals Llc Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning

Also Published As

Publication number Publication date
DK693475T3 (en)
HUT74100A (en) 1996-11-28
HU9502146D0 (en) 1995-09-28
ZA9506118B (en) 1996-05-31
AU2713895A (en) 1996-02-08
CN1077566C (en) 2002-01-09
FI114704B (en) 2004-12-15
EP0693475B1 (en) 1998-02-11
LU91793A9 (en)
AU685644B2 (en) 1998-01-22
SI0693475T1 (en) 1998-06-30
KR100364465B1 (en) 2003-02-05
FI953523D0 (en)
EP0693475A1 (en) 1996-01-24
JPH0899939A (en) 1996-04-16
JP2007084574A (en) 2007-04-05
FI953523A0 (en) 1995-07-21
LTPA2011007I1 (en) 2018-08-10
HK1005062A1 (en) 1998-12-18
RU95113154A (en) 1997-06-27
US6344558B1 (en) 2002-02-05
HU218481B (en) 2000-09-28
IL113901A (en) 1999-05-09
KR960004315A (en) 1996-02-23
BR9502390A (en) 1996-02-27
PL309734A1 (en) 1996-02-05
CO4410179A1 (en) 1997-01-09
FI114704B1 (en)
LU91793I2 (en) 2011-05-02
ES2115298T3 (en) 1998-06-16
PE34896A1 (en) 1996-09-07
PL181169B1 (en) 2001-06-29
RU2150465C1 (en) 2000-06-10
US20020010178A1 (en) 2002-01-24
DK0693475T3 (en) 1998-09-23
USRE39593E1 (en) 2007-04-24
DE4426245A1 (en) 1996-02-22
CZ286441B6 (en) 2000-04-12
AT163176T (en) 1998-02-15
GR3026326T3 (en) 1998-06-30
CA2154424A1 (en) 1996-01-24
CZ190495A3 (en) 1996-05-15
JP4034366B2 (en) 2008-01-16
CA2154424C (en) 2008-04-15
DE59501431D1 (en) 1998-03-19
JP4846552B2 (en) 2011-12-28
NZ272623A (en) 1996-02-27
FI953523A (en) 1996-01-24
CN1125221A (en) 1996-06-26
MY114889A (en) 2003-02-28
US6248737B1 (en) 2001-06-19

Similar Documents

Publication Publication Date Title
DE69530493D1 (en) Ablationsgerät
DE69531947D1 (en) Ausbreitbare ringprothese
GB2294043B (en) Bisresorcinyltriazines
DE69528655D1 (en) Asymmetrische femorale prothese
DE69524254D1 (en) Nadelmagazin
DE69502378D1 (en) Metalloproteinaseinhibitoren
DE69529412D1 (en) Hydromorphone-therapie
DE69512891D1 (en) Metalloproteinaseinhibitoren
DE69532245D1 (en) Imidazolderivat
DE69512030D1 (en) Cerebral-dilator
DE59508177D1 (en) Modulare hüftgelenkprothese
DE69528457D1 (en) Modulares blockwand-haltesystem
GB2293823B (en) 2-Hydroxyphenyltriazines
DE69522947D1 (en) Phenylxanthin-derivate
DE69531859D1 (en) Bioumbaubare collagentransplantat prothese
DE69523560D1 (en) Fluorinzelle
DE69534962D1 (en) Htk-ligand
DE69534778D1 (en) Cathepsin-02-protease
DE69533314D1 (en) Polyester-isolation
DE69526822D1 (en) Xanthin-derivate
GB2298422B (en) Compounds and their use
DE69506554D1 (en) Schrumpfbares originalitätsband
EP0696731A3 (en) Cytoanalyzer
PH30348A (en) Azaquinoxalines and their use
HRP970680B1 (en) New ketobenzamides and their use

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXTF Application for patent extension filed

Filing date: 20140902

PEL Intension of commissioner to extend period of protection

Free format text: PRODUCT NAME: TAPENTADOL(AS HYDROCHLORIDE

Extension date: 20190715

EXTG Patent extension order granted

Extension date: 20190715